The Development of a Human Model of Respiratory Syncytial Virus Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Wellcome Trust
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT01349543
First received: May 5, 2011
Last updated: June 14, 2012
Last verified: June 2012
  Purpose

The aim of this study is to understand the immune response (how the body fights infection) to Respiratory Syncytial Virus (RSV). This virus usually causes a simple 'common cold' illness in healthy adults, but can cause wheezing and lung problems in young infants and the elderly. The investigators want to understand why this is, in order to develop vaccines and treatments.

Participants will include 30-40 healthy adults age 18-55 years. Study procedures will include brief medical exams, breathing tests, a diary of symptoms, blood tests, samples of fluid (lavage) and cells from the nose, throat and lungs. All participants will receive the virus via drops in the nose. The duration of the study for all subjects will be 6 weeks.


Condition Intervention
Respiratory Syncytial Virus Infections
Respiratory Viral Infections
Biological: RSV A Memphis 37

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Development of a Human Model of Respiratory Syncytial Virus Infection

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Host response to RSV challenge [ Time Frame: Prior to and 0-28 days post challenge ] [ Designated as safety issue: No ]
    The host response to RSV challenge will be assessed daily for 14 days using methods such as symptom diaries, volume of nasal secretions, numbers of inflammatory cells in nasal mucus, and levels of chemical mediators in nasal fluids. This will be compared with that at baseline and at 28 days post challenge.


Estimated Enrollment: 40
Study Start Date: May 2011
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Viral Challenge Biological: RSV A Memphis 37
Intranasal administration
Other Name: M37

Detailed Description:

Bronchiolitis is the commonest cause of hospital admission in infants. It is caused by Respiratory Syncytial Virus(RSV), a virus that causes mild 'common colds' in adults, but can cause lung inflammation and difficulty breathing in infants and the elderly. In 2005, nearly 34 million cases in children <5 years occurred, resulting in 3.4 million hospital admissions,and around 120,000 deaths. There is no vaccine, and some previous vaccines actually made the disease worse.

The investigators have been trying to understand why for 40 years. Advances in immunology have given us a completely different way of looking at inflammation: rather than studying what causes it, the investigators now want to know what regulates it. Much of what the investigators know about how what causes and regulates inflammation has come from studies of animals, however, these do not exactly predict what happens in man.

The investigators therefore plan to infect healthy adult volunteers with RSV, and observe what happens in humans after RSV infection. The investigators will collect samples of blood, fluid and cells from the nose, throat, and lungs, and a diary of symptoms over four weeks. The investigators will analyse the blood, fluid, and cells to determine the important mechanisms that regulate inflammation in human RSV infection.

Studies like this have been conducted previously with no severe side effects. The investigators anticipate that the discoveries made in this research project will help us achieve a better understanding of what causes and regulates inflammation in RSV so that the investigators can learn ways to control it, with the aim of developing vaccines and treatments.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy persons aged 18 to 55 years, able to give informed consent

Exclusion Criteria:

  • Chronic respiratory disease (asthma, COPD, rhinitis, sinusitis) in adulthood
  • Inhaled bronchodilator or steroid use within the last 12 months
  • Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 6 months
  • Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks
  • Smoking in the past 6 months OR >5 pack-year lifetime history
  • Subjects with allergic symptoms present at baseline
  • Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease
  • Subjects with known or suspected immune deficiency
  • Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge
  • History of frequent nose bleeds
  • Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study
  • Pregnant or breastfeeding women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01349543

Contacts
Contact: Maximillian Habibi rsv-research@imperial.ac.uk

Locations
United Kingdom
St. Mary's Hospital, Imperial College London, Norfolk Place, Recruiting
London, United Kingdom, W2 1PG
Contact: Maximillian Habibi       rsv-research@imperial.ac.uk   
Sponsors and Collaborators
Imperial College London
Wellcome Trust
Investigators
Principal Investigator: Peter Openshaw Imperial College London
  More Information

No publications provided

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01349543     History of Changes
Other Study ID Numbers: JROSM0127
Study First Received: May 5, 2011
Last Updated: June 14, 2012
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
Respiratory syncytial virus
RSV
Immunology
Viral infection
Bronchiolitis
Viral challenge
Viral lung disease

Additional relevant MeSH terms:
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections

ClinicalTrials.gov processed this record on July 31, 2014